Earnings Call Summary | Inhibikase Therapeutics(IKT.US) Q1 2024 Earnings Conference
Earnings Call Summary | Inhibikase Therapeutics(IKT.US) Q1 2024 Earnings Conference
The following is a summary of the Inhibikase Therapeutics, Inc. (IKT) Q1 2024 Earnings Call Transcript:
以下是Inhibikase Therapeutics, Inc.（IKT）2024年第一季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
Inhibikase Therapeutics indicated a net loss for Q1 2024 of $4.6 million, or $0.73 per share, a minor increase from a net loss of $4.5 million, or $0.98 per share from the same period in 2023.
As of the end of Q1 2024, the company holds $9.7 million in cash and cash equivalents, expected to sustain operations till November 2024.
Inhibikase Therapeutics表示，2024年第一季度的淨虧損爲460萬美元，合每股虧損0.73美元，較2023年同期的450萬美元淨虧損或每股虧損0.98美元略有增加。
截至2024年第一季度末，該公司持有970萬澳元的現金及現金等價物，預計將持續運營至2024年11月。
Business Progress:
業務進展：
Significant strides are being achieved in the Phase 2, 201 trial for Risvodetinib or Risvo in Parkinson's disease, with patient enrollment to conclude in June and top-line data slated for H2 2024.
Constructive engagements with two FDA divisions for their Imatinib project program, IkT-001Pro, aiming at exploring potential opportunities in pulmonary arterial hypertension and gastroenterological and hematological cancers.
An innovative antibody targeting a key marker of alpha-synuclein pathology in Parkinson's disease is under development, which could potentially improve pathology tracking and elimination.
Following a pre-IND meeting with the FDA, the potential application of IkT-001Pro as a PAH treatment was discussed, highlighting potential approval pathways and the possibility of receiving novel chemical entity status for the drug in treating PAH.
瑞沃地替尼或瑞斯沃治療帕金森氏病的2期201期試驗取得了重大進展，患者入組將於6月結束，主要數據定於2024年下半年公佈。
與美國食品藥品管理局的兩個部門就其伊馬替尼項目計劃IKT-001Pro進行了建設性合作，旨在探索肺動脈高壓以及胃腸病學和血液系統癌症的潛在機會。
一種針對帕金森氏病中α-突觸核蛋白病理學關鍵標誌物的創新抗體正在開發中，它有可能改善病理跟蹤和消除。
在與美國食品藥品管理局舉行了IND前會議之後，討論了IKT-001Pro作爲多環芳烴治療的潛在應用，強調了潛在的批准途徑以及該藥物在治療多環芳烴方面獲得新化學實體地位的可能性。
More details: Inhibikase Therapeutics IR
更多詳情： 抑制酶療法 IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。